PROGRESS-AD

Active not recruitingPhase 2

Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

A Phase 2, Parallel Group, Randomized, Double- Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared With Placebo in Patients With Early Alzheimer's Disease

Lead sponsor

GlaxoSmithKline

Asset

GSK4527226

Listed sites

Recruiting sites

Enrollment

367

actual

Study population

Alzheimer’s disease

Key I/E criteria

•MCI due to AD / mild AD dementia•Amyloid biomarker required (PET/CSF)•MMSE 21-29•Brain MRI excludes >4 microhemorrhages, vasogenic edema

Primary endpoint

•Clinical Dementia Rating-Sum of Boxes (CDR-SB)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Registry2023-505083-11-00EU CT Number

Org study ID219867

NCT IDNCT06079190

Timeline

Milestones

Study first posted2023-10-12actual

Study start2023-10-20actual

Last update posted2025-11-14actual

Primary completion2026-09-30estimated

Study completion2026-11-23estimated

Assets

Drug assets

GSK4527226

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age50 Years

Maximum age85 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

Participant must be in the Alzheimer's continuum as defined by the 2018 National Institute on Aging and Alzheimer's Association (NIAAA) Research Framework corresponding to the clinical categories of MCI due to AD and mild AD dementia.

Participant must have evidence of amyloid positivity either by positive positron emission tomography (PET) result (Amyloid PET scans must be read by a central imaging lab) or cerebrospinal fluid (CSF) amyloid beta (Aβ) test result indicative of amyloid positivity

•Participants must also meet the following criteria for clinical severity:

1. MMSE score of between 21 and 29 points

2. CDR-global score (GS) of 0.5 to 1.0.

3. CDR Memory Box score greater than or equal to (≥) 0.5.

4. Participants with objective impairment in episodic memory as indicated by at least 1 standard deviation below age-adjusted mean in the Wechsler Memory Scale-IV Logical Memory II (WMS-IV LMII)

•If the participant is receiving symptomatic AD medications such as an Acetylcholinesterase inhibitor (AChEI) or memantine, the dosing regimen must have been stable for at least 12 weeks prior to screening and is not expected to change during study participation.

•If the participant is receiving other medications for AD related symptoms or associated conditions, the dosing regimen must have been stable for at least 4 weeks prior to screening and not expected to change during study participation. Symptoms must be considered adequately and stably controlled by the investigator, without marked changes in medication anticipated for the duration of the study.

•Body weight ≥ 45 kilogram (kg) to less than or equal to (≤)120 kg with body mass index (BMI) between 17 and 34.9 kilogram per meter square (kg/m^2), inclusive.

•A female participant is eligible to participate if she is not pregnant or breastfeeding, and if of child-bearing potential follows contraception requirements outlined in the protocol

•A male participant is eligible to participate if he follows contraception requirements outlined in the protocol

•Willing and able to give informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

•Availability of an adult person who has frequent and sufficient contact with the participant is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to provide information at clinic visits, and signs the ICF of the study partner

Exclusion criteria

Participant has evidence of any neurological condition other than AD that may contribute to cognitive impairment.

•History or presence of vascular disease that has the potential to affect cognitive function.

•History or presence of stroke within the past 1 year or recent transient ischemic attack within 180 days before screening.

•History of severe, clinically significant central nervous system (CNS) trauma.

•History or presence of intracranial tumor.

•Presence of ongoing infection(s) that may affect brain function, or history of infections that resulted in neurologic sequelae.

•History of primary psychiatric diagnosis that the investigator considers may interfere with study assessments.

Columbia Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, suicidal behaviour or has been assessed to be at risk of suicide, in the opinion of the investigator within 6 months before screening, at screening, or at the Baseline visit, or has been hospitalized or treated for suicidal behaviour in the past 2 years.

•Participant has history of alcohol and/or moderate to severe substance use disorder within the past 2 years

•Magnetic resonance imaging (MRI) evidence based on central read of:

1. >3 lacunar infarcts.

2. Stroke involving a major vascular territory, severe small vessel, or white matter disease.

3. Any territorial /cortical/other infarct >1 cubic centimetre (cm^3).

4. White matter hyperintense lesions on the FLAIR sequence that correspond to an overall Fazekas score of 3

5. >4 microhaemorrhages.

6. Any areas of superficial (leptomeningeal) hemosiderosis.

7. A single macro-hemorrhage greater than 10 millimetres (mm) at greatest diameter.

8. Vasogenic edema.

9. Cerebral contusion, encephalomalacia, aneurysms, vascular malformations, or infective lesions.

10. Space occupying lesions or brain tumors.

11. Significant cerebral vascular pathology

12. Hydrocephalus/Normal pressure hydrocephalus.

13. Other MRI findings contraindicating participation in the study such as subarachnoid hemorrhage.

•History suggestive of exposure to, or past tuberculosis (TB) infection should undergo screening for TB disease.

•Chronic active immune disorder requiring systemic immunosuppressive therapy within 6 months prior to Screening.

•Screening serum vitamin B12 concentration < Lower limit of normal (LLN) or in the low normal range

•Folate <LLN or Thyroid-stimulating hormone (TSH) > Upper limit of normal (ULN)

•Hemoglobin A1c >8 percentage (%) or poorly controlled diabetes during the last 12 weeks

•History of cancer

•Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins

•Planned surgery during the study which requires general, spinal, or epidural anesthesia that would take place during the study.

•Known genetic predisposition for clotting disorder or hemorrhagic disease.

•Key exclusionary medications include:

-Antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood stabilizers, or stimulants that are used on a chronic basis, are exclusionary if not consistent with the following rule: treatment has to have been at a stable dose for at least 4 weeks before screening and should remain stable during the study

-Any biologic drugs with systemic exposure, whether investigational or approved, used within 6 months before screening Any disease modification drug for AD, such as aducanumab and lecanemab, whether investigational or approved, used within 6 months before screening.

-Anticoagulation medications within 90 days of screening and during the study

-Systemic immunosuppressive therapy within 6 months before screening and during the study.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Global cognition

Function / daily living

Memory

Global cognition

3 endpoints

Primary/protocol endpoint

Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Week 52, 64 and 76

Clinical Dementia Rating-Sum of Boxes (CDR-SB)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Integrated Alzheimer's Disease Rating Scale (iADRS) Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Weeks 52, 64 and 76

ADAS-Cog

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Alzheimer's Disease Composite Score (ADCOMS) for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Weeks 52, 64 and 76

ADAS-Cog

change from baseline, improvement

Memory

1 endpoint

Secondary/protocol endpoint

Change from Baseline in ADAS-Cog14 Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Weeks 52, 64 and 76

ADAS-Cog

change from baseline, improvement

Function / daily living

2 endpoints

Secondary/protocol endpoint

Change from Baseline in ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Weeks 52, 64 and 76

ADCS-Activities of Daily Living (ADCS-ADL)

change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in ADCS-iADL component of ADCS-ADL-MCI Score for Dose 1 vs Placebo Across Weeks 52, 64 and 76

Time frame:Baseline, Weeks 52, 64 and 76

ADCS-Activities of Daily Living (ADCS-ADL)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.